ASIA unversity:Item 310904400/86929
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 90120/105277 (86%)
造访人次 : 8144253      在线人数 : 2042
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/86929


    题名: Regulation and role of EZH2 in cancer.
    作者: Yamaguchi, H;Yamaguchi, H;洪明奇*
    贡献者: 生物科技學系
    关键词: EZH2;PRC2;Neoplasms;Genetic transcription;Untranslated RNA;MicroRNAs;Post-translational protein processing
    日期: 2014
    上传时间: 2014-11-07 14:52:26 (UTC+8)
    摘要: Polycomb repressive complex 2 (PRC2) is the epigenetic regulator that induces histone H3 lysine 27 methylation (H3K27me3) and silences specific gene transcription. Enhancer of zeste homolog 2 (EZH2) is an enzymatic subunit of PRC2, and evidence shows that EZH2 plays an essential role in cancer initiation, development, progression, metastasis, and drug resistance. EZH2 expression is indeed regulated by various oncogenic transcription factors, tumor suppressor miRNAs, and cancer-associated non-coding RNA. EZH2 activity is also controlled by post-translational modifications, which are deregulated in cancer. The canonical role of EZH2 is gene silencing through H3K27me3, but accumulating evidence shows that EZH2 methlyates substrates other than histone and has methylase-independent functions. These non-canonical functions of EZH2 are shown to play a role in cancer progression. In this review, we summarize current information on the regulation and roles of EZH2 in cancer. We also discuss various therapeutic approaches to targeting EZH2.
    關聯: BREAST CANCER RESEARCH AND TREATMENT;46(3):209-22.
    显示于类别:[生物科技學系] 期刊論文

    文件中的档案:

    档案 大小格式浏览次数
    index.html0KbHTML138检视/开启


    在ASIAIR中所有的数据项都受到原著作权保护.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈